((biliopancreatic or bilio?pancreatic or bilio pancreatic) and diversion

Appendix 2: Assessment of transferability
The following transferability factors were considered: (1) methodological characteristics (perspective of cost assessment, discount rate, medical cost approach, productivity cost approach), (2) healthcare system characteristics (absolute and relative prices in healthcare, clinical practice variation, differences in resource use, incentives and regulations for health-care providers, technology availability), and (3) population characteristics (demography, disease incidence and prevalence, case-mix, life expectancy, health-status preferences, acceptance, compliance, incentives to the patients and productivity and work-loss time).
Appendix 3: The adaptation of costs
This method was developed on behalf of the Swiss Federal Office of Public Health in order to estimate the cost of non-communicable diseases (NCDs) in Switzerland. The project was assessing the costs of NCDs using two approaches: one based on Swiss healthcare registries and data and the second based on the available national and international literature [1] . We took this method further to understand the impact on other disease. For this study we take an example of bariatric surgery versus conservative treatment for obesity and overweight. We present step-by-step methodology how to adapt international cost-effectiveness analysis to a single country. Fifteen studies were found to be qualitatively transferable to Switzerland and provided sufficient information on costs and effects. The included studies were performed in 11 countries (Austria, Finland, France, Germany, Italy, Portugal, Spain, Sweden, United Kingdom, Australia, and USA), with costing years ranging from 1999 to 2012).
Resource utilisation
The statistics of healthcare expenses per capita provided by the OECD and corrected for purchasing power was used. A correction factor between Switzerland and the countries in which the selected cost-effectiveness analyses were performed has been calculated (more concretely, the current expenditure on health per capita in Switzerland in a defined year was divided by the expenditure on health in the other countries for the same year). Table below summarizes the correction factors used for the bariatric surgery example.
Prices of healthcare services
Prices of healthcare services: the correction for different healthcare prices across countries was corrected through the purchasing power parity. As for the resource utilisation correction, a correction factor was calculated. 
Change in cost over time
The final correction step was performed using the yearly growth rates of total Swiss healthcare expenditures. To simplify the calculations, the overall health care cost changes depending on a reference year (1999) were calculated. In the case of a specific disease and set of treatment strategies, costs may change over time due to mere price changes but no changes in resource utilisation, or resource utilisation for the treatment of the disease of interest may also change. In our 'base case' approach, we assumed the latter, and that changes in resource utilisation occur with the same cost impact as at the level of total Swiss health care expenditures.
The resulting correction was based on the yearly growth rates of total Swiss healthcare expenditures, as reported by the Swiss Federal Office of Statistics (Swiss FSO 2015a). In a sensitivity analysis, we alternatively assumed no change in resource utilisation over time. The resulting, alternative correction was thus based on the change in Swiss price levels. General instead of healthcare-specific change in price levels was used, as the reporting of the latter may have been influenced by recent changes in the methodology applied by the Swiss FSO [1] . The adaptation of cost data representing indirect costs followed a similar approach. However, the first of the above-described steps is irrelevant in the case of indirect costs. The third step was based on the change in Swiss salaries over time (Swiss FSO 2015b) [2] . The Swedish Obese Subjects (SOS) study for long-term [30] National publications (in particular 2011)
Clegg 2003 [7]
HTA (Clegg 2002 ) including 17 RCT and 1 cohort study (the Swedish Obese Subjects (SOS) study) [25] Economic evaluation of orlistat (Hakim 2002 Australian studies [26, 27] Economic evaluation of orlistat [ 
31] Pollock 2013 [16]
Australian study [26] UK 
